New Zealand markets close in 6 hours 23 minutes

Novo Nordisk A/S (NVO)

NYSE - Nasdaq Real-time price. Currency in USD
Add to watchlist
107.35+1.18 (+1.11%)
At close: 4:00PM EDT
107.35 0.00 (0.00%)
After hours: 04:41PM EDT
Full screen
Trade prices are not sourced from all markets
Previous close106.17
Bid106.82 x 800
Ask110.00 x 800
Day's range105.45 - 107.71
52-week range63.22 - 107.71
Avg. volume1,018,512
Market cap246.511B
Beta (5Y monthly)0.28
PE ratio (TTM)35.89
Earnings dateN/A
Forward dividend & yield1.47 (1.39%)
Ex-dividend date16 Aug 2021
1y target estN/A
  • GlobeNewswire

    Novo Nordisk A/S – Share repurchase programme

    Bagsværd, Denmark, 25 October 2021 – On 4 August 2021, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) and the Commission Delegated Regulation (EU) 2016/1052 of 8 March 2016 (the "Safe Harbour Rules"). This programme is part of the overall share repurchase programme of up to DKK 18 billion to be executed during a 12-month period beginning 3 February 2021. Under the programme i

  • GlobeNewswire

    Scott+Scott Attorneys at Law LLP Investigates Novo Nordisk A/S’s Directors and Officers for Breach of Fiduciary Duties – (NVO)

    NEW YORK, Oct. 06, 2021 (GLOBE NEWSWIRE) -- Scott+Scott Attorneys at Law LLP (“Scott+Scott”), an international securities and consumer rights litigation firm, is investigating whether certain directors and officers of Novo Nordisk A/S (“Novo Nordisk”) (NYSE: NVO) breached their fiduciary duties to Novo Nordisk and its shareholders. If you are a Novo Nordisk shareholder, you may contact attorney Joe Pettigrew for additional information toll-free at 844-818-6982 or Scot

  • GlobeNewswire

    Novo Nordisk A/S: Trading in Novo Nordisk shares by board members, executives and associated persons on 10 August 2021

    Bagsværd, Denmark, 11 August 2021 — This company announcement discloses the data of the transaction(s) made in Novo Nordisk shares by the company’s board members, executives and their associated persons in accordance with Article 19 of Regulation No. 596/2014 on market abuse. The company’s board members, executives and their associated persons have given Novo Nordisk power of attorney on their behalf to publish trading in Novo Nordisk shares by the company’s board members, executives and their a